Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM,NASDAQ:SMMT), adds a bit of extra detail to their announcement this week around the interim data for their treatment for Duchenne Muscular Dystrophy (DMD).
The interim results for the PhaseOut study revealed a "statistically significant and meaningful" reduction in muscle damage in patients taking the company's treatment, ezutromid.
''We're really pleased ... I wouldn't say we're surprised as we believe in the technology and we've been really hopeful that we're going to be able to make a huge impact on this really nasty disease that affects so many young men''.
Meet Reward Minerals Ltd, Recce Ltd, Rimfire Pacific Mining NL and Aus Tin Mining at our event, Melbourne, 31 January 2018.Register here >>